It has been another successful year for PQE Group, which closed in 2021 with a turnover of +18% compared to the previous year. PQE Group’s continued growth in 2021 is due to an increase in portfolio services and the adoption of digital technology for service delivery, such as smart glasses, which allowed work to be done from remote locations during the lockdown.
The company reached 1100 employees worldwide in 2021 as a result of the recruitment of more than 600 people, split between recent graduates (mainly in Italy) and senior experts. This trend is expected to continue in 2022, with a further increase reaching 1900 employees by December. The only difference will be on a geographic scale. To develop a larger organization, the PQE Group focused on its Italian activities and location in 2021. However, 2022 will be the year of focusing on the global locations, especially in the United States and Mexico, where a 250% personnel increase is expected. In addition, in Europe, the company aims to develop the offices opened in 2021 in France, Belgium, Poland, and Spain.
The development plan also includes the opening of new offices in the United States and Southeast Asia.
In the organizational framework, the Partnership League was established by CEO D’Incerti and the Board of Directors: PQE employees who wish to become partners can follow a planned career roadmap. This five-level pyramid structure is divided between equity partners and associates, with several benefits associated with it. An ambitious plan that already announced the appointment of 120 talented young managers – 40% of whom are women – as Associates at the beginning of 2022; selected not only for their professional skills but also for their proactive attitude towards the company. A recognition that will allow them, in the following years, to have increasingly crucial and strategic roles within the company and to grow as Equity Partners in one of the Group’s branches.
PQE Group, a leader in the Lifesciences services business since 1998, will formally compete with the world’s leading consulting companies in 2022, establishing itself as one of the top five global players focusing in the pharmaceutical sector.